Natco Pharma Ltd. — Capital/Financing Update 2022

Jan 20, 2022

==> picture [451 x 46] intentionally omitted <==

20[th] January, 2022

Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Dalal Sreet, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith the Press Release under Regulation 30 of SEBI (LODR) Regulations, 2015 for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

ADINARAYANA MADINEEDI Digitally signed by ADINARAYANA MADINEEDI DN: c=IN, st=Telangana, 2.5.4.20=a008497813275d4124d2b42c9f7f924b5b96346aa8741a90d57d102d95c690c8, postalCode=500017, street=12-13-266 street no 2 Lane no 9 Tarnaka secunderabad, pseudonym=52398da71daa6f1de479ec9618474b70, serialNumber=3da487f04b8912870dea3f277d9e87fc06da96e80b36d2beb1428dfe3f665de7, o=Personal, cn=ADINARAYANA MADINEEDI Date: 2022.01.20 15:15:36 +05'30' M Adinarayana Company Secretary & Vice President (Legal and Corp Affairs)

Encl : as above

Ref: PR/22/2021-2022

==> picture [454 x 46] intentionally omitted <==

NATCO announces License Agreement with the Medicines Patent Pool

Hyderabad, India, January 20, 2022

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has signed a non-exclusive licenses agreement with the Medicines Patent Pool (MPP), Switzerland. MPP had taken license from Merck Sharp & Dohme Corp. (MSD), USA for the same.

Natco with this license agreement can manufacture and sell molnupiravir Capsules 200 mg. for Indian market, which will be sold under brand name MOLNUNAT ® for treatment of Covid 19 infection with Sp02>93% and who have high risk of progression of the disease including hospitalization or death.

This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name. Under the license, Natco can set its own price for the generic products it produces, paying a royalty on sales to MSD. MSD, Ridgeback Biotherapeutics and Emory University will not receive royalties for sales of molnupiravir under this agreement for as long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.

Forwarded for favour of publication For NATCO Pharma Limited

ADINARAYANA MADINEEDI Digitally signed by ADINARAYANA MADINEEDI DN: c=IN, st=Telangana, 2.5.4.20=a008497813275d4124d2b42c9f7f924b5b96346aa8741a90d57d102d95c690c8, postalCode=500017, street=12-13-266 street no 2 Lane no 9 Tarnaka secunderabad, pseudonym=52398da71daa6f1de479ec9618474b70, serialNumber=3da487f04b8912870dea3f277d9e87fc06da96e80b36d2beb1428dfe3f665de7, o=Personal, cn=ADINARAYANA MADINEEDI Date: 2022.01.20 15:16:13 +05'30' M Adinarayana Company Secretary & Vice president (Legal & Corp Affairs)